Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus gemcitabine versus gemcitabine alone for advanced or metastatic epithelial ovarian cancer after platinum-resistant first-line therapy or in third line
MOH_2018-04-17_002310Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in epithelial ovarian cancer (EOC) comparing Masitinib + gemcitabine with Gemcitabine alone (2 arms). Primary endpoints: Overall survival and Efficacy. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
masitinibgemcitabine
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on MOH_2018-04-17_002310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-17_002310.